Frontage Holdings Appoints New Co-CEOs

Frontage Holdings Corporation has announced significant changes in its leadership. Dr. Abdul Mutlib, the current CEO, will transition to the role of Chief Scientific and Strategy Officer. He will be succeeded by Dr. Wentao Zhang and Dr. John Lin, who have been promoted to Co-CEOs. The announcement marks a pivotal moment in Frontage's leadership succession plan.

Dr. Mutlib's move is aimed at ensuring a smooth transition and business continuity. He will continue serving Frontage for at least a year, focusing on strategic growth, particularly in early drug discovery. Dr. Zhang has been with Frontage for nearly four years, while Dr. Lin brings over 17 years of experience. Both have proven track records of leadership and will share clear, delineated responsibilities as Co-CEOs.

Dr. Song Li, Executive Chairman, expressed confidence in the new leadership duo, underscoring their executive experience and effective collaboration. Dr. Mutlib emphasized his appreciation for the opportunity to serve and his faith in the new Co-CEOs to lead Frontage forward.